Fig. 6: PD-1 and CTLA4 interactions are decreased in plaques of type 2 diabetic (T2D) patients.
From: Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors
a, Schematic depiction of IC interaction analyses in atherosclerotic plaque immune cells from T2D versus nondiabetic patients (n = 22). b, Proportion of major cell identities found in human plaques by scRNA-seq, stratified by diabetes status. *P = 0.036. c, Proportions of CD274- or CD86-expressing myeloid cell subclusters engaging in the strongest significant interactions with PD-1 or CTLA4. Boxes represent interquartile ranges; center lines depict medians. Each dot represents a patient. Whiskers below and above boxes represent extent of lower and upper quartiles, respectively. P values in b and c were determined by unpaired, two-tailed Student’s t-tests (n = 9 nondiabetic and n = 13 T2D). d,e, Dot plot of differential PD-L1 (encoded by CD274)–PD-1 (encoded by PDCD1) (c) or CD86–CTLA4 (d) interaction probabilities in T2D versus nondiabetic patients (P < 0.05). P values were calculated by the CellChat package (v.1.1.3) in R (v.4.0.3).
